JP2021529814A5 - - Google Patents
Info
- Publication number
- JP2021529814A5 JP2021529814A5 JP2021500661A JP2021500661A JP2021529814A5 JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5 JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cycloalkyl
- heterocycloalkyl
- alkyl
- cancer
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695384P | 2018-07-09 | 2018-07-09 | |
| US62/695,384 | 2018-07-09 | ||
| PCT/IB2019/055811 WO2020012339A1 (en) | 2018-07-09 | 2019-07-08 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529814A JP2021529814A (ja) | 2021-11-04 |
| JPWO2020012339A5 JPWO2020012339A5 (https=) | 2022-07-15 |
| JP2021529814A5 true JP2021529814A5 (https=) | 2022-07-15 |
Family
ID=67997654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500661A Pending JP2021529814A (ja) | 2018-07-09 | 2019-07-08 | 化学化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210253528A1 (https=) |
| EP (1) | EP3820843A1 (https=) |
| JP (1) | JP2021529814A (https=) |
| CN (1) | CN112424167A (https=) |
| BR (1) | BR112021000332A2 (https=) |
| CA (1) | CA3105942A1 (https=) |
| WO (1) | WO2020012339A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| PE20220572A1 (es) * | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| CN115190813B (zh) | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| EP4232447A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| RS66455B1 (sr) | 2020-10-22 | 2025-02-28 | Evotec Int Gmbh | Modulatori puta integrisanog odgovora na stres |
| EP4232153A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1343782B1 (en) | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| AU2003254157A1 (en) * | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| WO2007109107A2 (en) * | 2006-03-17 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Atf4 as a therapeutic target in alzheimers disease and other neurological disorders |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| WO2016001390A1 (en) * | 2014-07-02 | 2016-01-07 | Inflectis Bioscience | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins |
| JP2017197433A (ja) * | 2014-09-12 | 2017-11-02 | 石原産業株式会社 | ニコチン酸エステル化合物、農園芸用殺菌剤及び植物病害の防除方法 |
| TWI763668B (zh) * | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| US20190298705A1 (en) * | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| BR112020000122A2 (pt) * | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
-
2019
- 2019-07-08 WO PCT/IB2019/055811 patent/WO2020012339A1/en not_active Ceased
- 2019-07-08 CA CA3105942A patent/CA3105942A1/en active Pending
- 2019-07-08 EP EP19770173.3A patent/EP3820843A1/en not_active Withdrawn
- 2019-07-08 CN CN201980046203.5A patent/CN112424167A/zh active Pending
- 2019-07-08 US US16/973,587 patent/US20210253528A1/en not_active Abandoned
- 2019-07-08 BR BR112021000332-0A patent/BR112021000332A2/pt not_active Application Discontinuation
- 2019-07-08 JP JP2021500661A patent/JP2021529814A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529814A5 (https=) | ||
| JP2019521111A5 (https=) | ||
| JP2019521109A5 (https=) | ||
| RU2018146946A (ru) | Химические соединения | |
| RU2018145734A (ru) | Химические соединения в качестве ингибиторов atf4 пути | |
| JP7158382B2 (ja) | Ｃ－ｋｉｔ阻害剤としてのアミノチアゾール化合物 | |
| ES2202658T3 (es) | Heterociclos sustituidos que contienen nitrogeno como inhibidores de la proteina-quinasa p38. | |
| JP6227707B2 (ja) | Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 | |
| AU2014222756B2 (en) | Inhibitors of histone demethylases | |
| KR100737090B1 (ko) | 축합 이미다졸륨 유도체 | |
| RU2018113430A (ru) | Производные l-фенилпирролидин-2-она в качестве ингибиторов perk | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| CN106243023A (zh) | 用于抑制nampt的胍化合物和组合物 | |
| JP2021512059A5 (https=) | ||
| AU2018338098B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| JPWO2020012339A5 (https=) | ||
| US9255072B2 (en) | Pyrazole compounds and thiazole compounds as protein kinases inhibitors | |
| RU2007133111A (ru) | Соединения, ингибирующие raf, и способы | |
| JP2020525513A (ja) | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 | |
| JP2009513703A5 (https=) | ||
| JPH11269146A (ja) | 分化誘導剤 | |
| RU2014150338A (ru) | Соединение как ингибитор передачи сигналов wnt, его композиции и применение | |
| JP2017537948A5 (https=) | ||
| US20150284347A1 (en) | New benzene sulfonamide thiazole compounds | |
| BR112015006686A2 (pt) | combinação de regorafenib e ácido acetilsalicílico para o tratamento de câncer. |